Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N, Konnai S, Hosoya K, Kim S, Kinoshita R, Deguchi T, Owaki R, Tachibana Y, Yokokawa M, Takeuchi H, Kagawa Y, Takagi S, Ohta H, Kato Y, Yamamoto S, Yamamoto K, Suzuki Y, Okagawa T, Murata S, Ohashi K. Maekawa N, et al. Among authors: kim s. PLoS One. 2023 Oct 4;18(10):e0291727. doi: 10.1371/journal.pone.0291727. eCollection 2023. PLoS One. 2023. PMID: 37792729 Free PMC article.
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. Maekawa N, et al. Among authors: kim s. NPJ Precis Oncol. 2021 Feb 12;5(1):10. doi: 10.1038/s41698-021-00147-6. NPJ Precis Oncol. 2021. PMID: 33580183 Free PMC article.
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.
Maekawa N, Konnai S, Asano Y, Sajiki Y, Deguchi T, Okagawa T, Watari K, Takeuchi H, Takagi S, Hosoya K, Kim S, Ohta H, Kato Y, Suzuki Y, Murata S, Ohashi K. Maekawa N, et al. Among authors: kim s. Sci Rep. 2022 Jun 3;12(1):9265. doi: 10.1038/s41598-022-13484-8. Sci Rep. 2022. PMID: 35665759 Free PMC article.
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.
Deguchi T, Maekawa N, Konnai S, Owaki R, Hosoya K, Morishita K, Nakamura M, Okagawa T, Takeuchi H, Kim S, Kinoshita R, Tachibana Y, Yokokawa M, Takagi S, Kato Y, Suzuki Y, Murata S, Ohashi K. Deguchi T, et al. Among authors: kim s. Cancers (Basel). 2023 Jun 1;15(11):3013. doi: 10.3390/cancers15113013. Cancers (Basel). 2023. PMID: 37296981 Free PMC article.
Canine Transforming Growth Factor-β Receptor 2-Ig: A Potential Candidate Biologic for Melanoma Treatment That Reverses Transforming Growth Factor-β1 Immunosuppression.
Takeuchi H, Konnai S, Maekawa N, Takagi S, Ohta H, Sasaki N, Kim S, Okagawa T, Suzuki Y, Murata S, Ohashi K. Takeuchi H, et al. Among authors: kim s. Front Vet Sci. 2021 Jun 14;8:656715. doi: 10.3389/fvets.2021.656715. eCollection 2021. Front Vet Sci. 2021. PMID: 34195245 Free PMC article.
Diverse genome-wide DNA methylation alterations in canine hepatocellular tumours.
Asari Y, Yamazaki J, Thandar O, Suzuki T, Aoshima K, Takeuchi K, Kinoshita R, Kim S, Hosoya K, Ishizaki T, Kagawa Y, Jelinek J, Yokoyama S, Sasaki N, Ohta H, Nakamura K, Takiguchi M. Asari Y, et al. Among authors: kim s. Vet Med Sci. 2023 Sep;9(5):2006-2014. doi: 10.1002/vms3.1204. Epub 2023 Jul 22. Vet Med Sci. 2023. PMID: 37483163 Free PMC article.
119,454 results
You have reached the last available page of results. Please see the User Guide for more information.